Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Walid Shalata; Alexander Yakobson; Rachel Steckbeck; Ashraf Abu Jama; Omar Abu Saleh; Abed Agbarya

doi:10.3390/curroncol29010016

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Walid Shalata, Alexander Yakobson, Rachel Steckbeck, Ashraf Abu Jama, Omar Abu Saleh, Abed Agbarya

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

In the following report, we describe a case of alkaline phosphatase (ALP) elevation occur-ring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification.

Original language	English
Pages (from-to)	173-177
Number of pages	5
Journal	Current Oncology
Volume	29
Issue number	1
DOIs	https://doi.org/10.3390/curroncol29010016
State	Published - 1 Jan 2022

Keywords

ALK mutation
Alecensa® (Alectinib)
Alkaline phosphatase (ALP)
Lung adenocarcinoma
Toxicity

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/curroncol29010016

Cite this

@article{b30a7545d70140d79282f35d6b796ce4,

title = "Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?",

abstract = "In the following report, we describe a case of alkaline phosphatase (ALP) elevation occur-ring during treatment with alectinib (Alecensa{\texttrademark}), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification.",

keywords = "ALK mutation, Alecensa{\textregistered} (Alectinib), Alkaline phosphatase (ALP), Lung adenocarcinoma, Toxicity",

author = "Walid Shalata and Alexander Yakobson and Rachel Steckbeck and {Abu Jama}, Ashraf and {Abu Saleh}, Omar and Abed Agbarya",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

day = "1",

doi = "10.3390/curroncol29010016",

language = "English",

volume = "29",

pages = "173--177",

journal = "Current Oncology",

issn = "1198-0052",